Obsidian Therapeutics IPO

obsidiantx.comHealthcare / BioTech & Pharma

Obsidian Therapeutics is a clinical-stage biotechnology specializing in engineered cell and gene therapies with a mission to deliver transformative outcomes for patients with intractable diseases. The company utilizes drug-responsive domains for controlled protein function in therapeutics, aiming for targeted treatment solutions. Obsidian Therapeutics was founded by Michael Gilman, Steve Shamah, and Tariq Kassum in 2015 and is headquartered in Cambridge, MA.

Buy or sell Obsidian Therapeutics stock Learn more about Obsidian Therapeutics stock

Learn more about Obsidian Therapeutics

Is Obsidian Therapeutics a publicly traded company?

Obsidian Therapeutics is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Will Obsidian Therapeutics go IPO?

Obsidian Therapeutics has not yet filed for an IPO. However, it's important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or through mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is Obsidian Therapeutics's IPO price?

The IPO price for Obsidian Therapeutics will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.

Can you invest in Obsidian Therapeutics pre-IPO?

Obsidian Therapeutics is privately held company and is not publicly traded, therefor investing in Obsidian Therapeutics pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to invest in private companies before their potential IPO. If you are not an accredited investor, discover how to begin the the process to potentially qualify for new investment opportunities.

What is the value of my Obsidian Therapeutics shares?

To determine the value of your Obsidian Therapeutics shares, create a free account to gain access to Forge’s platform. Forge Markets contains pricing information for hundreds of pre-IPO companies. A Private Market Specialist will also be available to assist you with any inquiries related to your Obsidian Therapeutics shares. You can also learn more about how to sell your private shares before getting started.

Can you sell Obsidian Therapeutics before it goes public?

Yes, you can seek to sell shares in Obsidian Therapeutics while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

When was Obsidian Therapeutics founded?

Obsidian Therapeutics was founded in 2015.

Who are Obsidian Therapeutics's major investors?

Wellington Management

Atlas Venture

Ra Capital Management

Takeda Ventures

Bristol Myers Squibb

Foresite Capital

Woodline Partners

Novo Holdings

Janus Henderson Investors

Amgen Ventures

Logos Capital

Samsara Biocapital

Soleus Capital

RTW Investments

Deep Track Capital

Blue Owl Capital

TCG Crossover Management

Johnson & Johnson Innovation

Surveyor Capital

Vertex Ventures HC

Revelation Partners

Cowen Healthcare Investments

Pivotal Life Sciences

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.